Higher-dose semaglutide 7.2 mg delivers about 21% weight loss

On June 21, 2025, Novo Nordisk reported that a higher dose of its semaglutide injection — 7.2 mg once weekly — produced average weight loss of about 21% in adults with obesity, with roughly one in three participants losing 25% or more of their starting body weight ^[1]. The results came from the phase 3b STEP UP trial program and became the basis for a later US filing and approval of the higher-dose product, marketed as Wegovy HD ^[1][2].

What the trials measured

STEP UP (NCT05646706) ran 72 weeks and enrolled 1,407 adults with obesity, randomly assigned to semaglutide 7.2 mg, semaglutide 2.4 mg, or placebo, all on top of a lifestyle program ^[2]. A companion trial, STEP UP T2D (NCT05649137), enrolled about 512 adults who had both obesity and type 2 diabetes and used the same three treatment groups ^[2]. Full results from both trials were published in The Lancet Diabetes & Endocrinology in November 2025 ^[2].

The headline numbers vary depending on which figure is cited, and the sources do not fully reconcile them. Novo Nordisk's June 2025 announcement described average weight loss of 21%, with a third of participants reaching 25% or more ^[1]. Novo's March 2026 approval release cited 20.7% mean weight loss ^[2]. AJMC, summarizing the published trial data, reported 18.7% mean weight loss with semaglutide 7.2 mg versus 3.9% with placebo at 72 weeks, and said 31.2% of participants achieved at least 25% weight reduction ^[2]. Different statistical approaches — for example, results among people who stayed on treatment versus everyone randomized — commonly explain gaps like this, but the sources here do not spell out which method produced which number.

In people who also had type 2 diabetes, the effect was smaller. STEP UP T2D showed 13.2% mean weight loss with the 7.2 mg dose compared with placebo, and 21.3% of patients lost 20% or more ^[2].

Side effects at the higher dose

Novo and outside reviewers described the overall safety picture as consistent with earlier semaglutide trials and broadly comparable to the 2.4 mg dose ^[2]. Gastrointestinal problems were the most common adverse events, and both GI events and dysesthesia — abnormal skin sensations such as tingling or burning — were more frequent at 7.2 mg than at lower doses ^[2]. In STEP UP T2D, dysesthesia was reported in 18.9% of people on 7.2 mg, compared with 4.9% on 2.4 mg and 0% on placebo ^[2].

Why it matters for patients

Before this dose existed, people taking Wegovy injections topped out at 2.4 mg weekly. Some people lose much less than the trial averages at that dose. The 7.2 mg option gives clinicians a way to escalate within the same drug class — a step that may be considered for people whose response to 2.4 mg is judged inadequate, before moving to other approaches such as bariatric surgery ^[2].

The tradeoff visible in the data is that more weight loss came with more side effects, particularly stomach-related problems and the sharp jump in dysesthesia reports ^[2]. Those are conversations to have with a prescriber, not decisions to make from trial averages.

Several practical questions are not answered in these sources: what Wegovy HD costs, how insurers will handle coverage or prior authorization for the higher dose, and whether the 7.2 mg dose carries the same cardiovascular risk-reduction indication that Wegovy 2.4 mg has.

What happened next

The STEP UP results were published in The Lancet Diabetes & Endocrinology in November 2025 ^[2]. On March 19, 2026, the FDA approved Wegovy HD (semaglutide 7.2 mg) for long-term weight reduction in adults with obesity, or overweight plus at least one weight-related condition ^[1][2]. It was the fourth product cleared under the FDA Commissioner's National Priority Voucher pilot program and the first GLP-1 approved that way ^[2]. A US launch in a single-dose pen was expected in April 2026 ^[2]. The 7.2 mg dose was already approved in the EU and UK ^[2].